-
Similar Content
-
By SMILLER
We have been having problems for the last month or so with D-dimer QC on our TOPS analyzers. We are using the regular HemosiL reagents and controls, and no matter what we do, the QC runs with a Mean close to the upper insert range limit on both controls. Does anyone else have this problem?
We have been using these analyzers and IL products for over a year and now this happens. We are wondering if the formulation of the QC has changed. Once reconstituted, they are supposed to be good for a month in the fridge -- it appears to us that they may be only reliable for about a day.
Thanks, Scott
-
By heathervaught
I need some guidance! I did a quick search of the forums for any discussion about this, and the most current posting was in 2010. I'm wondering if anyone has any new information, new experiences, or any advice about CAP TRM.40120. The note states "...all analysts participate in QC on a regular basis."
How frequently is "regular"? For example, when I was looking to complete our annual Competency assessment in September (don't ask...), I was looking for evidence that each individual who performs MTS testing had performed MTS QC. There were some employees who had not performed MTS QC yet in 2016. I'm inclined to say that someone who hasn't performed QC in at least 8+ months is not participating in QC on a regular basis. Being new to my role, I'm just not sure how the assessors interpret this standard, and how others provide evidence of compliance.
-
By jeloweryii
Hemo bioscience, an established and growing biotechnology company headquartered in Research Triangle Park (RTP), North Carolina, develops and manufactures immunohematology reagents and related products for the world wide transfusion diagnostics market. Our customers include industry partners, reference laboratories, buying groups, hospital blood banks, and donor centers. Hemo bioscience's in-house research, development and manufacturing activities are led by blood bank trained scientists who are committed to improving the science of transfusion technology.
When life depends on reliable results, you can rely on Hemo bioscience - "The science in blood banking"
-
By Lingkwyz
Hi guys,
I haven't been exposed as a blood banker for quite some time, so please bear with me. Recently, our institution had a case of transfusion reaction (lower back pain) with one unit of PRBCs. The testing details are as follows:
History: Non-specific reaction (Multiple encounters)
Pre Transfusion Sample
Solid Phase : 2 of 3 cels 2+ (Positive
Gel Card (Regular) : Negative
Gel Card (Enzyme) : Negative
Dx: Non-Specific Reaction, all siginificant antibodies excluded
Transfusion Reaction Investigation Sample
Solid Phase : 2 of 3 cels 2+ (suggestive with Anti-Jka)
Gel Card (Regular) : Positive (2+) Minimum grade (Clear-cut Anti-Jka)
Gel Card (Enzyme) : Positive (4+) (Clear-cut Anti-Jka)
DAT (Gel Card) : Positive
Elution Testing: Anti-Jka Detected
Dx: Anti-Jka
Analyzing the encounter, me and a colleague, through curiosity re-ran the Pre Transfusion Sample:
Pre Transfusion Sample: (Curiosity Run)
Solid Phase : 2 of 3 cels 2+ (suggestive with Anti-Jka)
Gel Card (Regular) : Positive ; Wp Minimum grade (suggestive with Anti-Jka)
Gel Card (Enzyme) : Positive ; 1+ Minimum grade (suggestive with Anti-Jka)
Taking all details, I could presume that the Gel Card results (both regular and enzyme, which I believe was ran at the same time) of the 1st Pre Transfusion Sample was the jinx. So confidence to the testing method lies to the daily QC of the Gel Card which was ran first thing of the day. Now, I'm asking, if Solid-phase technology could incorporate a positive control and negative control to each strip of testing, why aren't there any on the Gel Card Method? Next, if the Solid-phase technology could also incorporate a "system trap" to ensure the addition of patient's sample to the testing, through it's Capture LISS, why cant the Gel Card do so? I believe that seeing an all-negative resulted panel would be enough for some people for exclusion. Lastly, if reagents aren't available for the Gel card method to ensure the addition of plasma, should our institution enforce a backup procedure that could ensure the reviewer that none of the essential components of the testing (e.g. Patient's plasma) is not missed?
Hoping for the masters..
Thanks !
lingkywz
-
By seraph44
Hello Blood Bankers,
I recently ran into my first unsatisfactory Antigen typing QC. A tech performed QC for an "e" antisera using a heterozygous cell. Results were negative at IS and negative after 5 min incubation. This was repeated by the same tech and later repeated by myself:Results did not change.
The "e" antisera was ran with a different heterozygous cell and results were negative at IS and 2+ after 5 min incubation. Both the cells and the antisera were near expiration date. However, I'm a bit confused as to what corrective action is needed. How do I prove my panel cells are working correctly and how do I prove my antisera is working correctly?
I think I proved my antisera is working correctly by running it with another Hetero cell. Should I run my panel cell with a new antisera to prove the panel is "e" positive?
Thank you,
Serafin
-